BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, August 2, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

In the clinic for Oct. 26, 2022

Oct. 26, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Applied, Astrazeneca, Atai, Avrobio, Can-Fite, Cardiol, Gristone, Imaginab, Inotrem, Oblato, Quadriga, Seelos and Ultimovacs.
Read More
IV drip

Inotrem’s nangibotide shines in curtailed COVID-19 trial

Oct. 25, 2022
By Cormac Sheridan
Inotrem SA obtained an unexpectedly robust efficacy signal from a curtailed phase II trial of nangibotide, an inhibitor of triggering receptor expressed on myeloid cells 1, in patients with severe COVID-19.
Read More

Positive phase III clinical trial data for Sinocelltech’s COVID-19 vaccines

Oct. 25, 2022
By Zhang Mengying
Sinocelltech Group Ltd. has reported positive interim data for two COVID-19 vaccine candidates, SCTV-01C and SCTV-01E, from phase III trials in the United Arab Emirates.
Read More

Regulatory actions for Oct. 25, 2022

Oct. 25, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Acumen, Astrazeneca, Daiichi, JJP, Leo, Merck & Co., Novaliq, Novavax, Sensorion, Vanda, Vaxxinity.
Read More

In the clinic for Oct. 25, 2022

Oct. 25, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alpine Immune, Bio-Path, Cincor, Matinas, Mirum, Morphic, NS, Novartis, Phathom, Scholar Rock, Step, Tricida, Vaxcyte, Vaxxinity, Viiv, Viridian, Zentalis.
Read More
Antibodies attacking SARS-CoV-2 virus
Infection

Discovery of novel broadly neutralizing MAb against SARS-CoV-2

Oct. 25, 2022
Researchers from Emory University have discovered a novel broadly neutralizing SARS-CoV-2 antibody, 002-S21F2, being developed as a potential anti-coronavirus therapeutic.
Read More

Conference data for Oct. 24, 2022: IDWeek

Oct. 24, 2022
New and updated preclinical and clinical data presented by biopharma firms at IDWeek, including: Basilea, F2G, Ferring, Merck, Scynexis, Seres, Veru.
Read More

Regulatory actions for Oct. 21, 2022

Oct. 21, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Biontech, Covis, Leo, Moderna, Novavax, Pfizer, Revance, Tvardi.
Read More

Other news to note for Oct. 21, 2022

Oct. 21, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Altamira, Kite, Novocure, Refuge, Zilentin.
Read More

In the clinic for Oct. 21, 2022

Oct. 21, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AM-Pharma, Harbour, Iterum, Medicane, Palatin, Spikimm, Talaris, T-knife, Venatorx, Vivacelle, Xeris.
Read More
Previous 1 2 … 71 72 73 74 75 76 77 78 79 … 553 554 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 31, 2026.
  • HIV virus

    AIDS 2026: New targets for metabolic dysfunction despite ART

    BioWorld
    Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
  • Jingxin discloses new muscarinic and sigma receptor agonists

    BioWorld Science
    Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
  • Silhouette illustration of DNA gene editing

    Death in Chinese gene-editing trial exposes ethical fault lines

    BioWorld
    The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
  • Anthony Fauci at Senate hearing 7-29

    Fauci’s silence may put him in contempt of Congress

    BioWorld
    After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing